Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1718-1729

  Bines, J ^a   Oleske, D M ^a   Cobleigh, M A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GOSERELIN; LEVAMISOLE; LUTEINIZING HORMONE; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; TAMOXIFEN; THIOTEPA; VINCA ALKALOID; VINCRISTINE;

ADULT; AGE; AGED; AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; DOSE RESPONSE; FEMALE; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; OLIGOMENORRHEA; ORAL DRUG ADMINISTRATION; OVARY FUNCTION; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0029864362     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1718     Document Type: Review

References (91)

1. Parker SL, Tong T, Bolden S: Cancer Statistics, 1995. CA Cancer J Clin 46:5-27, 1996
2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
3. Rose DP, Davis TE: Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1:1174-1176, 1977
4. Rose DP, Davis TE: Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 40:4043-4047, 1980
5. Samaan NA, deAsis Jr. DN, Buzdar AU, et al: Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 41:2048-2087, 1978
6. Mehta RR, Beattie CW, Das Gupta TK: Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 20:125-132, 1991
7. Dnistrian AM, Schwartz MK, Fracchia AA, et al: Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 51:803-807, 1983
8. Hankey BF, Miller B, Curtis R, et al: Trends in breast cancer in younger women in contrast to older women. Monogr Natl Cancer Inst 16:7-14, 1994
9. Higgins S, Haffty BG: Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer 73:2175-2180, 1994
10. Theriault RL, Sellin RV: Estrogen-replacement therapy in younger women with breast cancer. Natl Cancer Inst Monogr 16:149-152, 1994
11. Speroff L, Glass RH, Kase NG: Menopause and postmenopausal hormone therapy, in Speroff L, Glass RH, Kase NG (eds): Clinical Gynecologic Endocrinology and Infertility (ed 5). Baltimore, MD, Williams & Wilkins, 1994, pp 583-636
12. Food and Drug Administration: Labeling Guidance for Estrogen Drug Products. Patient Package Insert. Rockville, MD, FDA, 1992
13. Reichman BS, Green KB: Breast cancer in young women: effect of chemotherapy on ovarian function, fertility and birth defects. Monogr Natl Cancer Inst 16:125-129, 1994
14. World Health Organization: Technical Report Series 670: Research on the Menopause. Geneva, Switzerland, WHO, 1991
15. American College of Obstetricians and Gynecologists: Hormone replacement therapy. ACOG Tech Bull 166:1-8, 1992
16. Mezrow G, Rebar RW: The menopause, in Sciarra JJ, Droegemueller W (eds): Gynecology and Obstetrics, vol 1 (rev ed). Philadelphia, PA, Lippincott, 1994, pp 1-21
17. Cohen I, Speroff L: Premature ovarian failure: Update. Obstet Gynecol Surv 46:156-162, 1991
18. MacMahon B, Worcester J: Age at menopause: United States 1960-1962. US Vital and Health Statistics Series I, No. 19, Rockville, MD, The National Center for Health Statistics, 1966
19. Brincker H, Mouridsen HT, Andersen KW, et al: Castration induced by cytotoxic chemotherapy. J Clin Oncol 7:679-680, 1989 (letter)
20. Goldhirsch A, Gelber RD, Castiglione M: The magnitude of endocrine of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1:183-188, 1990
21. Koyama H, Wada T, Nishizawa Y, et al: Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409, 1977
22. Fisher B, Sherman B, Rockette H, et al: L-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: Lack of association of disease-free survival with depression of ovarian function. Cancer 44:847-857, 1979
23. Padmanabhan N, Wang DY, Moore JW, et al: Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Clin Oncol 23:745-748, 1987
24. Valagussa P, Moliterni A, Zambetti M, et al: Long-term sequelae from adjuvant chemotherapy. Recent Results Cancer Res 127:247-255, 1993
25. Carbone PP: Breast cancer adjuvant therapy. Cancer 66:1378-1386, 1990
26. Fisher B, Ravdin RG, Ausman RK, et al: Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168:337-356, 1968
27. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63:799-803, 1991
28. Bonadonna G, Rossi A, Valagussa P: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. World J Surg 9:707-713, 1985
29. Tormey DC, Gray R, Taylor SG IV, et al: Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. Natl Cancer Inst Monogr 1:75-80, 1986
30. Padmanabhan N, Howell A, Rubens RD: Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 2:411-414, 1986
31. Reyno LM, Levine MN, Skingley P, et al: Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer 29A:21-23, 1993
32. Boccardo F, Rubagotti A, Bruzzi P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multi-centric Italian study. J Clin Oncol 8:1310-1320, 1990
33. Toma S, Repetto L, Giacchero A, et al: Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients. J Chemother 4:321-325, 1992
34. Mouridsen HT, Rose C, Brincker H, et al: Adjuvant systemic therapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Recent Results Cancer Res 96:117-128, 1984
35. Ludwig Breast Cancer Study Group: Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 3:1059-1067, 1985
36. American College of Obstetricians and Gynecologists: Amenorrhea. ACOG Tech Bull 128:1-7, 1989
37. Wentz AC: Amenorrhea: Evaluation and treatment, in Jones HW III, Wentz AC, Burnett LS (eds): Novak's Textbook of Gynecology (ed 11). Baltimore, MD, Williams & Wilkins, 1988, pp 351-377
38. Bonadonna G, Valagussa P, Rossi A, et al: CMF adjuvant chemotherapy in operable breast cancer, in Salmon SS, Jones SE (eds): Adjuvant Therapy in Cancer II. New York, NY, Grune & Stratton, 1979, pp 227-235
39. Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45:4454-4459, 1985
40. Brincker H, Rose C, Rank F, et al: Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 5:1771-1778, 1987
41. Tormey DC: Endocrine effects of adjuvant chemotherapy in premenopausal women: suggestions for the future. Recent Results Cancer Res 115:106-112, 1989
42. Dowsett M, Richer J: Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients. Oncology 48:215-220, 1991
43. Sherman BM, Wallace R, Jochimsen PR: Hormonal regulation of the menstrual cycle in women with breast cancer: Effect of adjuvant chemotherapy. Clin Endocrinol 10:287-296, 1979
44. Reichman BS, Green KB: Breast cancer in young women: Effect of chemotherapy on ovarian function, fertility and birth defects. Monogr Natl Cancer Inst 16:125-129, 1994
45. Sobrinho LG, Levine RA, DeConti RC: Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol 109:135-139, 1971
46. Miller III JJ, Williams GF, Leissring JC: Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am J Med 50:530-535, 1971
47. Morgenfeld MC, Goldberg V, Parisier H, et al: Ovarian lesions due to cytostatic agents during the treatment of Hodgkin's disease. Surg Gynecol Obstet 134:826-828, 1972
48. Warne GL, Fairley KF, Hobbs JB, et al: Cyclophosphamide-induced ovarian failure. N Engl J Med 289:1159-1162, 1973
49. Schilsky RL, Lewis BJ, Sherins RJ, et al: Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 93:109-114, 1980
50. Chapman RM: Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 9:84-94, 1982
51. Damewood MD, Grochow LB: Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 45:443-459, 1986
52. Gradishar WJ, Schilsky RL: Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 16:425-436, 1989
53. Delrio G, De Placido S, Pagliarulo C: Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori 72:53-61, 1986
54. Jordan VC, Fritz NF, Tormey DC: Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47:624-630, 1987
55. Murugesan K, Rao SVS, Vij U: Effect of chemotherapy on gonadal function in women with breast cancer. Indian J Med Res 87:42-45, 1988
56. Shalet SM: Effects of cancer chemotherapy on gonadal function of patients. Cancer Treat Rev 7:141-152, 1980
57. Collichio F, Pandya K: Amenorrhea following chemotherapy for breast cancer: Effect on disease-free survival. Oncol 8:45-52, 1994
58. Rubens RD, Hayward JL, Knight RK et al. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet 1:839-843, 1983
59. Hortobagyi GN, Buzdar AU, Marcus CE, et al: Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. Natl Cancer Inst Monogr 1:105-109, 1986
60. Tancini G, Valagussa P, Bajetta E, et al: Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials 2:285-292, 1979
61. Beex LVAM, Mackenzie MA, Raemaekers JMM, et al: Adjuvant chemotherapy in premenopausal patients with primary breast cancer: Relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. Eur J Cancer Clin Oncol 24:719-721, 1988
62. The International Breast Cancer Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. Ann Oncol 1:30-35, 1990
63. Richards MA, O'Reilly SM, Howell A: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol 8:2032-2039, 1990
64. Tormey DC, Gray R, Gilchrist K, et al: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients: An Eastern Cooperative Oncology Group Trial. Cancer 65:200-206, 1990
65. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
66. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991
67. Zambetti M, Bonadonna G, Valagussa P, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-negative and estrogen receptor-negative breast cancer patients. Natl Cancer Inst Monogr 11:77-83, 1992
68. Scottish Cancer Trials Breast Group, ICRF Breast Unit, Guy's Hospital, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish Trial. Lancet 341:1293-1298, 1993
69. Cobleigh MA, Bines J, Lincoln ST, et al: Amenorrhea following adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 13:A55, 1994 (abstr)
70. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. N Engl J Med 332:901-906, 1995
71. Cobleigh MA, Bines J, Harris D, et al: Amenorrhea following adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 14:A158, 1995 (abstr)
72. Sutton R, Buzdar AU, Hortobagyi GN: Pregnancy and off-spring after adjuvant chemotherapy in breast cancer patients. Cancer 65:847-850, 1990
73. Brincker H, Mouridsen HT, Andersen KW: Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat 3:91-95, 1983
74. Spitz S: The histological effects of nitrogen mustards on human tumors and tissues. Cancer 1:383-398, 1948
75. Louis L, Lemaryi LR, Best WR: Treatment of chronic granulocytic leukemia with myleran. Arch Int Med 97:299-308, 1956
76. Sherins RJ: Gonadal Dysfunction, in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 2395-2406
77. Kay HH, Mattison DR: How radiation and chemotherapy affect gonadal function. Contemp Obstet Gynecol 26:109-127, 1985
78. Averette HE, Boyce GM, Girl MA: Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA 40:199-209, 1990
79. Plowchalk DR, Mattison DR: Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol 107:472-481, 1991
80. Santoro A, Bonadonna G, Valagussa P, et al: Long-term resuits of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
81. Shenkenberg TD, Von Hoff DD: Possible mitoxantrone-induced amenorrhea. Cancer Treat Rep 70:659-661, 1986
82. Shamberger RC, Rosenberg SA, Seipp CA, et al: Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep 65:739-746, 1981
83. Levine MN, Gent M, Hryniuk WM: A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 8:1217-1225, 1990
84. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
85. Bonadonna G, Rossi A, Valagussa P, et al: The CMF program for operable breast cancer with positive axillary nodes: Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 39:2904-2915, 1977
86. Ravdin PM, Fritz NF, Tormey DC, et al: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026-1029, 1988
87. Forbes JF: Long-term effects of adjuvant chemotherapy in breast cancer. Acta Oncol 31:243-250, 1992
88. Wenger NK, Speroff L, Packard B: Cardiovascular health and disease in women. N Engl J Med 329:247-256, 1993
89. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 265:1861-1867, 1991
90. Goldman L, Tosteson ANA: Uncertainty about postmenopausal estrogen: Time for action, not debate. N Engl J Med 325:800-802, 1991 (editorial)
91. Davidson NE: Ovarian ablation as treatment for young women with breast cancer. Monogr Natl Cancer Inst 16:95-99, 1994